OPTION: A Trial to Assess the Safety & Efficacy of MS1819 in Patients With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis

NCT03746483 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

41

Enrollment

INDUSTRY

Sponsor class

Conditions

Exocrine Pancreatic Insufficiency (EPI)
Cystic Fibrosis (CF)

Interventions

DRUG: MS1819
DRUG: Porcine PERT

Sponsor

Entero Therapeutics